Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.

Background: The CIAO trial recently demonstrated a probable clinical benefit of omalizumab in the treatment of severe COVID-19; however, the mechanism underlying this benefit remains unclear. Therefore, we sought to longitudinally assess the impact of omalizumab on serum cytokines in CIAO trial patients to determine its mechanism of action.

Methods: Blood samples were collected on days 0, 2, 7, and 14 from patients recruited into the CIAO trial and who consented to this substudy.

Epigenetics of concussion: A systematic review.

Background: Concussion is the most common neurological disorder affecting millions of people globally each year. Identifying epigenetic mechanisms influencing concussion incidence, severity and recovery could provide diagnostic and prognostic insight into this injury.

Objectives: This systematic review aims to identify the epigenetic mechanisms underpinning concussion.

Pneumothorax as the first presentation of multiple exostosis.

This article underscores the critical importance of thorough physical examinations and the need to investigate secondary causes in cases of refractory pneumothorax. The identification of hereditary multiple exostoses (HME) as the underlying condition highlights the necessity of considering rare etiologies, particularly in atypical presentations. While exostoses typically affect long bones, they can also involve the ribs and scapulae, leading to complications such as pneumothorax.